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Abstract Expression of CD20 antigen by the most of trans-
formed B cells is believed to be the driving force for targeting
this molecule by using anti-CD20 monoclonal antibodies.
While it is true that most lymphoma/leukemia patients can be
cured, these regimens are limited by the emergence of treatment
resistance. Based on these observations, development of anti-
CD20 monoclonal antibodies and combination therapies have
been recently proposed, in particular with the aim to optimize
the cytotoxic activity. Here we outline a range of new experi-
mental agents concerning the CD20 positive B-cell tumors
which provide high benefit from conventional therapy.
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Introduction
CD20 molecule is a phosphoprotein highly expressed on ma-
lignant B cells in non-Hodgkin lymphoma (NHL) and chronic
lymphocytic leukemia (CLL), making these malignancies
susceptible to immunotherapeutic strategies [1]. The exact
function of CD20 antigen is still unknown, but it is thought to
play roles in B-cell activation, differentiation and regulation of
calcium influx [2, 3]. Several recent studies have provided in-
teresting clues illustrating the importance of CD20 as an attrac-
tive target for immunotherapeutic strategies, including (i) high-
ly expression in over 90 % of neoplastic B cells, but not on
hematological stem cells or terminally differentiated plasma
cells, allowing clustered opsonization of tumor cells by mono-
clonal antibodies (mAbs), (ii) tight junction with plasma mem-
brane that contributes to binding of mAbs in close proximity to
the cell surface, (iii) lack of physiological ligands, which might
interfere with anti-CD20 mAb binding, and (iv) resistance to
internalization, shedding or much modulation upon binding by
an anti-CD20 antibody [4, 5]. Despite significant therapeutic
advances by using anti-CD20 antibodies such as rituximab,
most mature B-cell malignancies are also incurable and there
is a need for new therapies [6]. In an effort to improve the
outcome of CD20 targeted therapy in B-cell neoplasis, many
strategies such as antibody engineering approaches, radiother-
apy and cell based immunotherapy have been used. Moreover,
current clinical trials focus on combination therapies that are
even more effective for relapsed or progressive B-Lineage dis-
ease. We will review herein the treatment strategies for B-cell
malignancies to provide exciting opportunities for new and
improved therapeutics agents.
Biology of CD20 antigen
The CD20 antigen belongs to transmembrane protein of the
tetraspanin superfamily that is exclusively expressed on the
pre-B-cell stage, but is absent on plasma cells and hematopoi-
etic stem cells. The molecular biology of CD20 and its
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potential as a target for mAb therapy are key elements for its
clinical success [7].
Hydropathicity analysis of its sequence predicted three hy-
drophobic regions consisting: a tetraspan transmembrane mol-
ecule with two extracellular loops, a larger one of ~44 amino
acids between the third and fourth transmembrane regions,
and a much smaller one between the first and second hydro-
phobic domains as well as an intracellular N and C-terminal
regions with multiple consensus sequences for phosphoryla-
tion [8]. A better understanding of new epitope determination
within a desired part of human CD20 antigen using in silico
tools would be useful to develop synthetic peptide vaccines,
immunodiagnostic tests and mAbs with different binding
sites. Using phage display libraries, Binder et al. showed that
rituximab binds a discontinuous epitope within the extracellu-
lar segment of CD20, consisting (170) ANPS (173) and (182)
YCYSI (185), both strings brought in steric proximity by a
disulfide bridge between C (167) and C (183) [9].
Human CD20 is not glycosylated, but multiple isoforms
of this antigen resulting from differential phosphorylation
states with Mr of 33 kD (most abundant in normal
unstimulated canine peripheral B cells) and Mr of 34 to
36 kD (predominant forms seen in malignant B-cell lines)
have been identified [10]. Besides phosphorylation, respec-
tive palmitoylation of CD20 is required for its immune
activity and cell responses to anti-CD20 immunotherapy
[11]. Initially, CD20 has been considered unlikely to be
shed from the surface of cells, but subsequently it was
reported that this antigen is present at abnormal levels in
the sera of patients with NHL, both before and after first-
line non-mAb containing therapy [12]. Although the exact
biological function of CD20 has not yet been clarified, its
participation in the B-cell activation, differentiation and
regulation of calcium influx has been supposed. More
specifically, CD20 expression level in B-cell lines has
been reported to play a critical role in calcium influx
across the plasma membrane. A recent case report of a
patient with CD20 deficiency also suggested a central role
in the generation of T-cell-independent immune responses
[13, 14]. There is now overwhelming evidence that CD20
is physically and functionally associated to cellular signal-
ing cascades and display multiple interactions with specific
B-cell surface markers such as fibroblast growth factor
receptor 3 (FGFR3), CD40, B cell receptor (BCR), and
complement receptor CD21 [15, 16].
Developing therapeutic strategies for CD20+ B cells
Recombinant antibody engineering has become a popular
technology in the treatment of disorders over the last 30 years
[17]. The first report of antibody production specific for CD20
antigen (murine anti-CD20 B1) was introduced in 1980 and
since then several murine antibodies have been developed to
target this molecule. Rituximab, approved in 1997, was the
first anti-CD20 chimeric mAb used for treatment of patients
with several forms of B-cell–derived neoplasm as CLL, fol-
licular lymphoma (FL), mantle cell lymphoma (MCL) and
diffuse large B-cell lymphoma (DLBCL) [18].
Accumulating evidence indicates that some factors, includ-
ing CD20 cell-surface expression level, the presence of a
mutation/deletion in this antigen, CD20 protein phosphoryla-
tion rate [19], CD20 modulation/endocytosis [20], Lipid raft
composition [21], epigenetic regulation of the CD20 gene,
Fcγ Receptor (FcγR) and C1q genes polymorphisms [22,
23], expression of FcγRIIB, complement regulatory proteins
(CRP) CD59 and CD55 overexpression [24], Local tumor
burden [25], and cell adhesion mediated antibody resistance
(CAM-AR) are commonly associated with clinical benefit
from rituximab treatment. On the basis of what above report-
ed, scientific efforts are increasingly being focused on devel-
oping innovative tailored strategies to improve mAb-driven
cytotoxicity. We will provide an overview of these approaches
in the next sections.
Depleting neoplastic B cells with novel anti-CD20 mAbs
Based on their mode of CD20 binding and primary
mechanism of action for killing CD20-positive B-cell
neoplasms, anti-CD20 mAbs can be categorized into
type I (eg., rituximab, ofatumumab) and type II (eg.,
tositumumab, GA101) [26–33] (Table 1). Both types of
these antibodies are supposed to work mainly by medi-
ating antibody dependent cellular cytotoxicity (ADCC).
It is still not clear what characteristics are required for
the optimal reagent, but it is generally accepted that Fc-
dependent effector mechanisms are crucial for the effi-
cacy of anti-CD20 mAbs. As mentioned above, despite
effective antigen targeting capacity, rituximab usually
exhibit undesirable side-effects which restrict their appli-
cations in treatment of human diseases.
To overcome these drawbacks, effective anti-CD20 an-
tibodies are urgently needed [34–43] (Table 2). Central to
these findings are the implications for targeting this anti-
gen by using humanized antibodies. Obinutuzumab
(GA101) is a fully humanized glycoengineered type II
CD20 antibody which elucidates increased ADCC and a
higher degree of apoptosis than rituximab. More impor-
tantly, obinutuzumab induces lysosome-dependent cell
death in CLL cells receiving activation signals through
CD40-CD40 Ligand (CD40L) interactions [44]. The recent
efforts to understand the function of obinutuzumab indi-
cate that this agent significantly inhibits cell proliferation
and down-regulates PI3K/Akt and NF-κB signaling path-
ways as well as induces programmed cell death in primary
mediastinal large B-cell lymphoma (PMBL) [45]. A phase
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II, randomized trial of obinutuzumab monotherapy showed
significant efficacy, for 1000 mg as well as for 2000 mg,
in untreated CLL patients with no unexpected toxicities
[46].
Ofatumumab is another fully humanized anti-CD20 mAb
that recognizes membrane-proximal small-loop on CD20,
demonstrated greatest complement activation as compared
with rituximab and obinutuzumab [47].
Table 1 Major characteristic of
Type I (rituximab-like) and type II
(tositumomab-like) anti-CD20
antibodies
Type I antibodies Type II antibodies
Binding site: class I epitope 170 ANPS 173 in the large
extracellular loop, discontinuous epitope involving
the smaller extracellular loop of CD20 (position 72–
80) and position 159–166 in amino- terminal region
of the large loop
Binding site: class I epitope 172 P SEKNSP 178
Higher capacity to redistributes CD20 into lipid raft Lower capacity to cluster CD20 into membrane lipid
rafts
High CDC Less-potent mediators of CDC
ADCC activity ADCC activity
Full binding capacity Half binding capacity
Weak homotypic aggregation Evoke far more homotypic adhesion
Do not elicit efficient direct cell death More potently evoke PCD through actin
polymerization, lysosomal permeabilisation and
release of ROS and cathepsins
Induction of cytosolic calcium flux through B cell
antigen receptor signaling and the open type
conformation CD20
Do not cause calcium flux
FcγRII activation promoteing CD20 internalization No FcγRII activation resulting in reduced CD20
internalization modulation
ADCC antibody-dependent cellular cytotoxicity, CDC complement dependent cytotoxicity, PCD programmed
cell death, mAb monoclonal antibody, ROS reactive oxygen species
Table 2 Selected humanized
anti-CD20 mAbs in clinical
development for B-cell disorders
mAb Type In vivo studies/Indications tested ORR References
BM-ca I/II I/R/R NHL 33 % [34]
Ocaratuzumab I I low-affinity FcγRIIIa FL 50 % [35]
I/II low-affinity FcγRIIIa FL 30 % [36]
Obinutuzumab II II/NHL 55 % [37–40]
III/Obinutuzumab plus Chlorambuci CLL 78 %











Veltuzumab I R/R NHL I/II DBCL:43 % [41]
FL:44 %
MZL: 83 %
Ocrelizumab I I/II/R/R FL 38 % [42]
PRO131921 I I/R/R NHL 27 % [43]
I/II/CLL, iNHL
CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, iNHL
indolent non-Hodgkin lymphoma, mAb monoclonal antibody, ORR overall response rate, MCL Mantle cell
lymphoma, MZL marginal zone lymphoma, R/R NHL relapse or refractory non-Hodgkin lymphoma, NTC
Clinical trials.gov identifier: http://www.clinicaltrials.gov
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Ofatumumab in combination with bendamustine has ad-
vanced into phase III clinical trials for rituximab-resistant in-
dolent NHL patients (iNHL) [NCT01077518].
Based on published data by Doubek et al., ofatumumab–
dexamethasone (O-Dex) regimen exhibited significant clinical
benefit for patients with relapsed/refractory CLL, including
those with p53 abnormalities [48].
Veltuzumab is a humanized anti-CD20 mAb constructed
recombinantly on the framework regions of anti-CD22 mAb
epratuzumab could favor ADCC and apoptosis [49]. In a re-
cent report, subcutaneous administration of veltuzumab in 17
patients with refractory iNHL was well tolerated with no se-
rious side effects [50]. A phase I/II trial of veltuzumab and
milatuzumab, a humanized anti-CD74 antibody, was conduct-
ed in patients with relapsed or refractory B-cell NHL. In re-
gard to safety, immunotherapy-associated grade 3–4 adverse
events included anemia, atrial tachycardia, fatigue, hypergly-
cemia, infusion reactions, leukopenia, lymphopenia, and neu-
tropenia. Combination therapy resulted in overall response
rate 24 % with median duration of response 12 months [51].
A humanized anti-CD20 mAb ocrelizumab differs from
rituximab at the complementarity-determining regions
(CDRs), and shows lower complement dependent cytotoxicity
(CDC) but superior ADCC capacity as well as enhanced bind-
ing to the low-affinity variants of FcγRIIIa [52].
Ocaratuzumab (LY2469298, AME-133v) is a humanized
IgG1 anti-CD20 mAb engineered to have increased affinity
to CD20 and enhanced effector function in ADCC assays than
rituximab. This regimen in pretreated FL patients who were
low-affinity FcyRIIIa allele carriers, was generally well toler-
ated and common related adverse events included chills and
fatigue.
A partial or complete response (CR or PR) was observed in
22 % with a median progression-free survival (PFS) of
25.4 weeks. Ocaratuzumab showed a greater binding affinity
for CD20 and enhanced ability in mediating ADCC than ri-
tuximab [35].
A novel humanized anti-CD20 antibody BM-ca that binds
to distinct epitope 156–166 is most effective in ADCC and
anti-cell proliferation activities compared with rituximab and
ofatumumab [53]. To exploit this, data from phase I/II study of
12 patients with NHL suggested the drug had promising pre-
liminary anti-lymphoma effects, with 2 CR and 2 PR (33 %),
and well tolerated [34].
Development of bispecific antibodies
Bispecific antibodies (bsAb) offer a promising approach of
therapeutics over the next decade or so. These antibody for-
mats consisting two different binding arms (e.g., chemical
cross-linking or quadromas technique) that are able to redirect
immune cells to the tumor site and induce specific tumor cell
killing. Treatment of immunodeficient mice bearing human
NHL xenografts with CD20-CD22 bsAb (Bs20x22) led to
improvements in overall survival (OS) and the reduction of
tumor volume when compared to administration of each par-
ent mAb alone or combination rituximab and HB22.7 [54]. Of
particular note, targeting both CD20 and tyrosine kinase re-
ceptor FMS-related tyrosine kinase 3 (FLT3) (CD20-Flex) by
using bsAb was linked to infiltration of dendritic cells (DCs)
and cytotoxic T cells (CTLs) into tumor tissues, which could
provide long-term protection against recurrence of a tumor
[55]. CD47 × CD20 bsAb, that has reduced affinity for
CD47 relative to the parental antibody, provided selective
phagocytosis of NHL cells and recapitulate the synergy of
combination therapy [56].
BsAbs normally activate only a single class of accessory
cell and do not induce a long-lasting protective immunity that
is thought to lie in the lack of appropriate intact Fc part.
Therefore efforts to further increase therapeutic efficacy of
these antibody formats resulted in the development of
trifunctional bispecific antibodies (trAb) by using the Dock
and Lock (DNL) technology to create antibodies with higher
valency [57].
BsAbs are also being used to simultaneously retarget of
various effector cells such as T cells, NK cell, and macro-
phage. In agreement, Bi20 (FBTA05), a CD3 x CD20 trAb,
has been generated using the quadroma method that preferen-
tially binds to human activating FcγR+ accessory immune
cells via its Fc region. Bi20 was shown to be very efficient
in the in vitro eliminatation of Raji and NHL cell lines at
antibody concentrations as low as 0.5 ng/ml without the need
for any additional costimulation. Furthermore this agent me-
diates effective cytotoxicity against patient derived CLL cells
despite increased apoptosis resistance and low CD20 expres-
sion levels [58].
In efforts to bring NK cells and tumor cells in proximity,
[(CD20)2xCD16] has been constructed to target both CD20
and FcγRIIIA (CD16). The designed novel tribody showed
improved clearance of neoplastic B cells compared to rituxi-
mab both in vitro and in vivo, suggesting that this antibody
formatmay represent promising candidates for clinical appli-
cations [59].
Engineering antibody heavy chains for heterodimerization
seem likely to emerge as a successful strategy to overcome
bsIgG heavy chain-pairing problem.
The homodimerization of two heavy chains in an IgG is
mediated by introducing different mutations into two CH3
domains (e.g., knobs-into-holes strategy), resulting in asym-
metric antibodies. Anti-CD20/CD3 T cell-dependent bsAb
(CD20-TDB) comprises a full-length, humanized immuno-
globulin G1 molecule with near-native antibody architecture
constructed using Bknobs-into-holes^ technology. CD20-
TDB antibody showed superior anti-lymphoma/leukemia ac-
tivity both in vitro and in vivo even in the presence of high
concentrations of rituximab [60]. Double-variable domain
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(DVD)-Igs belong to symmetric bsIgG and IgG-like mole-
cules that have reached clinical development. DVD-Ig mole-
cules have been generated from two parent antibodies by
appending VL and VH domains of an IgG with the second
via short peptide linkers [61]. The recent creation of an anti-
CD20/human leukocyte antigen (HLA)-DR DVD-Ig is ex-
pected to have the added benefit of inducing ADCC and
CDC in vitro, demonstrating the potential of a tetravalent
IgG-like molecule as an alternate means to target B-cell lym-
phoma therapeutically [62].
To improve cross-linking, two novel bispecific hexavalent
antibodies (bsHexAbs) (HexAbs: IgG (Fab)4) namely
20-(74)-(74), 74-(20)-(20) derived from veltuzumab/
milatuzumab were developed through the DNL method.
Besides the potent cytotoxicity of both 20-(74)-(74) and
74-(20)-(20) antibodies against MCL cell lines as well as in
primary tumor cells from patients with MCL or CLL, these
bsHexAbs could also extended the survival of nudemice bear-
ing MCL xenografts [63].
Anti-CD20 antibody conjugates
Radioimmunoconjugates targeting CD20 antigen, RICsA
different way to improve antitumor efficacy of mAbs is to
attach them to radioactive and cytotoxic compounds, known
asimmunoconjugates.
Lymphoma cells are inherently radiosensitive; therefore, the
anti-CD20 radiolabeled antibodies as the first group of
immunoconjugates may provide a significant and durable re-
sponse advantage in comparison to naked (unlabeled) anti-
CD20 mAbs [64].
The approved RICs, anti-CD20 mAbs 90Y-ibritumomab
tiuexetan (Zevalin) and 131I-tositumomab (Bexxar) have been
used as single reagent or in combination with high-dose chemo-
therapy (as conditioning regimen) for the treatment of patients
with relapsed/refractory low-grade B-cell NHL or FL [65]. The
development of RIC with alpha-emitting radionuclides is attrac-
tive treatment option for B-cell NHL because of the high linear
energy transfer (LET) and shorter path length in human tissue
than the more commonly used beta-radiation, allowing higher
specific tumor cell kill and lower toxicity to healthy tissues.
The in vitro benefit of Bi-labeled rituximab has been further
underlined by a recent study using stable99mTc carbonyl
diethylene triamine penta acetic acid (DTPA)–rituximab conju-
gate that showed specificity and receptor affinity for CD20 anti-
gen on Raji cells, indicating its potential for further evaluation as
a purely NHL diagnostic agent [66]. Advanced in the treatment
era is pretargeted radioimmunotherapy (PT-RAIT), developed by
the DNL technology against CD20 for the treatment of NHL.
The explanation could lie in the fact, as Altieri performed in
xenografted nude mice that compared TF4, a humanized tri-
Fab bsAb with two Fabs binding CD20 and one Fab binding
histamine-succinyl-glycine (HSG), a pretargeting agent of an
111In-HSG-peptide with the directly conjugated 90Y-anti-CD20
IgG. The DNL tri-Fab recombinant construct demonstrated a
significant improved antitumor response with a >40 % cure rate
over that of the 90Y-anti-CD20 IgG directly radiolabeled anti-
CD20 IgG [67].
Anti-CD20-based cytotoxic drugs or toxins, ADCs
Antibodies have also been coupled to highly potent cytotoxic
drugs or toxins (ADCs) to provide a foothold for drug delivery
to corresponding antigen-positive cancer cells so as to in-
crease their cytotoxicity and decrease systemic drug exposure.
One such agent is rituximab- valine-citrulline antimitotic
monomethyl auristatin E (vcMMAE), which appended the
anti-CD20 properties of rituximab in lymphoma xenograft
models compared with mAb alone [68]. Similar results were
also obtained in CD20-positive mice bearing Ramos or Daudi
tumor xenografts after exposure to ofatumumab-vcMMAE
[69]. In addition, studies of rituximab-type I ribosome-
inactivating protein (RIP) saporin when combined with che-
motherapy was efficacious against Raji cell lines [70].
Anti-CD20 antibody-cytokine fusion protein, ICs Another
important research field is development of antibodies by
at taching cytokines to their Fc terminus, cal led
immunocytokines (ICs) to mediate greater NK-cell ADCC
through a higher affinity for CD16/FcγRIIIa. With efforts to
increase the stimulation activity of soluble IL15, a fusion pro-
tein linking IL15Rα chain sushi domain and human IL15
(RLI) has been generated. In agreement, a recent study using
RLI-RTX (rituximab) in mouse models of lymphoma, the
long-term survival versus either agent alone or in combination
was found to correlate with improved clinical efficacy of RTX
[71]. In addition to these treatment modalities, Rossi et al.
developed tetrameric IC comprising 4 Interferon-α2β
(IFN-α2βα) groups site-specifically attached to veltuzumab
via the DNLmethod. The potent therapeutic efficacy of mAb-
IFN-α ICs against human lymphoma xenografts models com-
pared favorably in activity with equidoses of the parent mAb,
the cytokine or an irrelevant IgG-IFN conjugate [72]. In vitro
experience with a bispecific IC 20-C2-2β consisting of two
copies of IFN α2β and a stabilized F (ab)2 of HLA-DR-
targeting humanized antibody hL243 has shown that this con-
jugate could effectively deplete a wide variety of malignant B
cells [73]. A recombinant anti-CD20-human interleukin-2
(hIL-2) IC (2B8-Fc-hIL2) based on the therapeutic rituximab
antibody scaffold expressed in Nicotiana benthamiana could
be effective in eliciting ADCC of lymphoma cells [74]
CD20 targeted therapy using nanotechnology
As an alternative to antibodies, multiple studies have focused
on providing selective delivery of therapeutic agents harbored
Invest New Drugs (2016) 34:497–512 501
by nanoparticle (NP) platforms. There is an interesting body
of work supported an in vitro significant decrease of BCL-2
protein expression level when the anti-CD20 antibody conju-
gated to gold nanoparticles (AuNP) through the spontaneous
reaction of the cysteine thiol groups [75].
A recent study using anti-CD20 coated gold NP and irra-
diating by a few resonant femtosecond pulses in vitro was able
to link high level of intracellular reactive oxygen species
(ROS) to apoptosis within several hours [76].
Guided byVoltan et al. work to develop NP for treatment of
SCID mice with a JVM-2 (p53wild-type B-leukemic cells) xe-
nografts, they designed three construction including Nutlin-3
as an anti-cancer agent in a variety of p53wild-type tumors
encapsulated into poly lactide-co-glycolide NPs (NP-Nut),
rituximab-engineered NPs (NP-Rt-Nut) and NPs engineered
with rituximab alone (NP-Rt). Of these, however, NP-Rt-Nut
prolonged the survival rates of mice more efficiently than NP-
Nut and/or NP-Rt [77]. The concept that antibody-conjugated
immunoliposomes might be a very promising delivery system
has also been reported in mice bearing human B lymphoma in
which CD20-targeted pegylated liposomal vincristine (VCR)
significantly prolonged survival rates compared with free
VCR CD20-targeted liposomal doxorubicin (DXR).
Additionally, 70 % remission rates through anti-CD19 and
anti-CD20-targeted liposomal VCR have been described in
this study [78].
Owing to its lower cardiotoxic potential, nonpegylated li-
posomal doxorubicin (NPLD) is given in combination with
rituximab, cyclophosphamide, vincristine, and, prednisone
(R-COMP) as a first-line treatment for splenic marginal zone
lymphoma (SMZL) leading to an ORR of 84 % [79, 80]. It is
now well documented that rituximab-conjugated liposomal
G3139 (an antisense ODN against Bcl-2) NPs could enhance
in vitro sensitivity of CLL cells to fludarabine and promote
significant in vivo antitumor activity [81]. Strikingly, the basic
research program elaborated N-(2-hydroxypropyl)
methacrylamide (HPMA) copolymer conjugates by using
modern controlled radical polymerisation technique, revers-
ible addition fragmentation chain transfer (RAFT) appears to
be effective against B-cell neoplasia. Support for these bene-
ficial effects comes from a recent study suggesting that mul-
tivalent HPMA copolymer conjugates attached to multiple
Fab’ fragments of the anti-CD20 mAb (1F5) exert significant
avidity and apoptotic activity during longer exposure times
compared to unconjugated whole mAb [82].
Cellular immunotherapy for B-cell malignancies
Adoptive transfer of endogenous T cells genetically modified
to express a chimeric antigen receptor (CAR) targeting CD20
antigen is an expanding area of interest within the field of
immunotherapy [83–85] (Table 3). Early generation CAR
bearing a CD20-targeted single-chain variable fragment
(scFv) and one signaling domain CD3ζ (scFvFczeta) demon-
strated antigen-specific IL-2 production as well as cytolytic
activity against human lymphoma in vitro [86]. These results
were confirmed in studies with engineered human cytotoxic T
lymphocytes (CTL) containing first generation CAR-CD20
which showed antigen-dependent interferon gama (IFN-γ)
secretion upon co-culture with CD20+ lymphoma stimulator
cells. Such CTL exhibit specific cytotoxicity against actual
tumor cells isolated from patients with a variety of B lymphoid
malignancies [87]. Wang et al., constructed a second-
generation CARs endowed with costimulatory endodomains
CD28 and a third-generation CAR containing a co-
stimulatory domain derived from CD28, CD137 (4-1BB) in
order to redirect them to tumor cells. These αCD19-BB-ζ
CARs were capable of promoting anti-lymphoma activity in
vitro compared with T cells expressing first generation CARs
[88]. Specifically, a third-generation 1F5 (anti-CD20)-
CAR containing an inducible iC9 and a truncated CD19
(Δ19) selectable marker has likewise demonstrated elimina-
tion of more than 90 % of the iC9-CD20 CAR- Δ19 T cells
upon activation of iC9 both in vitro and in vivo [89]. As an
alternative to T cells, NK cells have also been found to be
suitable effectors for expressing CARs directed against
CD20 in cell-based immunotherapy. Accordingly, NK cells
transduced with a chimeric receptor specific for CD20 share
the capacity to mediate increased cytotoxic activity against
primary lymphoma and leukemia cell lines as compared with
the control [90]. Similarly, the anti-CD20 CAR-expressing
NK-92 cells were found to be superior in controlling local
tumor growth of some neoplastic B-lymphoid xenografts in
immunocompromised mice [91]. The preclinical relevance of
expanded peripheral blood NK cells (exPBNK) modified with
anti-CD20 CAR following mRNA nucleofection has been
further underlined by the demonstration that CAR+ exPBNK
can significantly extended survival time (P<0.001) and re-
duce tumor size in human burkitt lymphoma xenografted
NOD/SCID/γ-chain−/− (NSG) mice [92]. Stem cell-based
therapies are emerging as a promising strategy to tackle can-
cer. Multiple stem cell types have been shown to exhibit in-
herent tropism towards tumors.Moreover, when engineered to
express therapeutic agents, these pathotropic delivery vehicles
can effectively target sites of malignancy. This perspective
considers the current status of stem cell-based treatments for
cancer and provides a rationale for translating the most prom-
ising preclinical studies into the clinic. Mesenchymal stem
cells (MSCs) transduced with anticancer peptides are current-
ly being explored for site-specific drug delivery to inhibit
tumor growth and progression. However, there are efforts to
overcome tumor-supportive properties and off-target effects
of MSCs, in order to make them as an attractive candidate
for cell-based therapy [93].
Human umbilical cord derived MSCs (HUMSCs) express-
ing scFvCD20-soluble tumor necrosis factor-related
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apoptosis-inducing ligand (sTRAIL) fusion protein have
shown potent preclinical efficacy in mice beating lymphoma
xenograft [94].
Targeting TNFSFR and CD20 antigen with fusion protein
The activation of tumor necrosis factor superfamily receptors
(TNFSFR) by their respective ligands or agonistic mAbs have
been proposed as being a potential target for cancer immuno-
therapy to induce tumor cell apoptosis via extrinsic pathway.
Interestingly, genetically fusing a rituximab-derived antibody
fragment to soluble FasL (scFv:sFasL) has been shown to
trigger apoptotic elimination of malignant B-cells upon
CD20 cross-linking [95]. To explore targeted delivery of sol-
uble trimeric CD40L (sCD40L) to the B cell leukemia marker
CD20 as a therapeutic option, scFvCD20:CD40L was gener-
ated. The scFvCD20:CD40L-based fusion protein augmented
effective paracrine maturation of DCs and also triggered a
significant decrease of cell viability in certain leukemic B cell
lines as a result of CD20-induced apoptosis [96].
Antibody-based combination therapy
Immunotherapy followed by stem cell transplantation
Tumor-specific mAbs when used in vivo in conjunction with
either autologous or allogeneic hematopoietic stem cell trans-
plantation (HSCT) represents a completely different approach
for the treatment of chemosensitive relapsed patients. Results
from several studies have reported that the addition of rituxi-
mab to second-line chemotherapy concurrent with autologous
hematopoietic stem cell transplantation (ASCT) improves
PFS than patients do not receive rituximab in their first-line
treatment. Accordingly, Magni et al., presented data from 15
patients with relapsed indolent lymphoma or MCL who were
treated with a combination of rituximab and high-dose che-
motherapy followed by ASCT. The efficacy of marrow treat-
ment was evaluated by PCR for the presence of t (14;18)
translocation before and after the purge. The results indicated
that all patients transplanted in this study had become negative
for the translocation and achieved at least a complete remis-
sion from induction therapy. Although a plethora of study
associated with encouraging results of maintenance rituximab
after ASCT have been described, the findings of
Gisselbrecht,s group revealed no significant survival advan-
tage in refractory DLBCL patients [97]. Furthermore, recent
studies established a link between the incorporation of
radioimmunotherapy in reduced-intensity conditioning (RIC)
allo-HSCT regimens and favorable outcome. The main reason
for this successful clinical translation lies in Dana Farber
Cancer Institute study which published the results of a pro-
spective trial of patients with relapsed, refractory or trans-
formed FL who received yttrium-90 (90Y)-ibritumomab
tiuxetan followed by fludarabine and low-dose busulfan RIC
allogeneic HSCT. The outcomes of 41 patients with FL were
considerably resulted in the 2-year OS, PFS and nonrelapse
mortality (NRM) were 83, 74, and 18 %, respectively. Based
on these results the incorporation of radioimmunotherapy
(RIT) in RIC allo-HSCT regimens is feasible because of the
excellent OS and PFS and acceptable rates of graft-versus-
host disease (GVHD) and relapse compared with regimens
that do not include RIT [98].
Cytokines combined with rituximab
Recent data support the concept that cytokines are the critical
cause of leukemic blast cell differentiation into professional
antigen-presenting cells initiating antitumor immune re-
sponses that make it a better target for immunotherapy.
These investigations raise the possibility that GM-CSF admin-
istered with R-CHOP (rituximab-cyclophosphamide,
vincristine, doxorubicin and prednisolone) can modestly im-
prove survival of previously untreated DLBCL in the elderly
[99]. In this regard, phase II study of rituximab plus GM-CSF
in patients with FL has already been completed, but no results
were reported [NCT01939730]. It was further observed that
Table 3 Clinical and preclinical studies of CD20–targeted CARs
CARs generation Receptor construct Associated malignancy Concomitant immunotherapy Results of in vivo studies References




2 CR, 1 PR, 4 SD;
all in NHL of 7
[84]
Second generation ScFv-41BB-CD3ζ Leukemia, Lymphoma recruiting [NCT01735604]
Third generation ScFv- CD28-41BB-CD3ζ R/FL, R/MCL Cyclophosphamide/IL-2 2 CR, 1 PR of 3 [85]
ASCTAutologous stem cell transplantation,CR complete response,DLBCL, diffuse large B-cell lymphoma, FL follicular lymphoma, IL-2 interleukin 2,
PR partial response, R/R iNHL relapsed or refractory indolent non-Hodgkin lymphoma,MCL mantle cell lymphoma, SD stable diseases, NTC Clinical
trials.gov identifier, http://www.clinicaltrials.gov
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the L19 antibody (specific for alternatively-spliced extra-do-
main B (EDB) of fibronectin)-mediated delivery of IL-2 to
tumor microenvironment isolated from phage display libraries
was able to completely eradicate B-cell lymphoma xenografts
when combined with rituximab [100]. Besides these cyto-
kines, a fusion protein consisting of IL15 mutant and IL-
15Rα/Fc complex could also improve rituximab-mediated
ADCC against B cell lymphoma both in vitro and in vivo
[101]. Therapeutic effects of ALT-803, an IL-15
Superagonist, in combination with rituximab is currently un-
de r c l in i ca l t r i a l fo r r e l apsed / r e f r ac to ry iNHL
[NCT02384954]. Moreover, the efficacy of rituximab plus
recombinant IL-21 was evaluated in a phase I trial, reporting
durable complete remissions in the subset of patients with
relapsed and refractory low grade B-cell lymphoproliferative
disorders [102].
Dendritic cell vaccine-based immunotherapy
Immunotherapeutic strategies have attempted to monopolize
on the efficient antigen-presenting capabilities of DCs to de-
liver ligands for activation of specific effector T cells as a
means of therapeutic vaccination in patients with advanced
cancers. Recent data have shown that the combination of ri-
tuximab and DC vaccine induces the generation of T-cell re-
sponses, leading to long-lasting antitumor immune protection
in syngeneic mouse lymphoma models [103]. Manzur et al.,
further highlighted that an enhanced therapeutic effect
of B cell-depleting anti-CD20 mAbs in lymphoma-
bearing mice when combined with DC vaccination
might be correlated with promotion of antigen cross-
presentation, induction of a protective T cell response,
and increased injected DCs activation through reducing
of tumor-derived IL-10 [104].
Exosome removal as a therapeutic adjuvant
for lymphoma/leukemia immunotherapy
Extensive analyses by various techniques have suggested that
exosome formation derived from tumor cells plays important
roles in regulating all facets of cancer development and spread
[105]. Activation of BCR triggers the release of CD20-bearing
tumor exosomes where they bind to anti-CD20, which protect
target cells from antibody attack [106]. In addition to interfer-
ing with the activity of immunotherapeutic agents, exosomal
survivin, the inhibitor of apoptosis (IAP) protein family, par-
ticipate in skewing T helper populations (Th1/Th2) and de-
creasing their cytotoxic function [107].
Interestingly, lymphoma-derived exosomes were found to
be modulated by lysosome-related, organelle associated ATP-
binding cassette transporter A3 (ABCA3) both in vitro and in
vivo. Consistent with this observations, the pharmacologic
silencing of ABCA3 using the cyclooxygenase type-2
inhibitor indomethacin abrogated exosome biogenesis, there-
by reducing exosome-mediated shielding of target cells and
increasing the anti-tumor efficacy of rituximab [108].
Therapeutic agents targeting cellular response to stress
and combinations
It has become increasingly evident that transformed cells al-
low acquiring a resistance to increased cellular stress condi-
tions in order to ensure cell survival and many homeostatic
functions. Depletion of significant survival proteins such as
Akt and cyclin D1 and thereby producing antitumour effects
in a wide range of lymphoma cell lines by pharmacologic
disruption of homeostatic molecules such as a ubiquitously
expressed chaperone, heat shock protein 90 (HSP90), has
gainedmore interest in recent years [109, 110]. It is commonly
believed that the ubiquitin-proteasome pathway is the major
process for the non-lysosomal intracellular proteins degrada-
tion also used to maintain homeostasis.
With regard to treatment, proteasome suppressant have
been shown to be critical for the inhibition of NF-κB activa-
tion which may also prevent angiogenesis and metastasis in
vivo and further increase the sensitivity of cancer cells to
apoptosis [111].
The induction of apoptosis by proteasome inhibitor,
bortezomib occurs following elevated apoptotic protease-
activating factor-1 (Apaf-1) expression in human leukemia
cells [112].
Supporting a potent role for proteasome inhibitors in cancer
cells, the results from the phase II study in elderly MCL pa-
tients clearly confirmed the benefit of adding bortezomib to
rituximab, doxorubicin, dexamethasone, and chlorambucil
(RiPAD+C) as a first-line therapy [113]. In another phase I/
II study bortezomib plus R-CHOP appears to produce clinical
advantage for non- germinal center B cell (GCB) DLBCL
subtype by enhanced activity of dose-adjusted chemotherapy
[114].
The mechanism by which leukemia cells were protected
against apoptosis induced by proteasome inhibitors seems to
be related to BCL-2 overexpression [115]. To overcome resis-
tance, the potential clinical administration of bortezomib, ri-
tuximab, and obatoclax, a novel pan-BCL-2 inhibitor, has
been shown to be effective in killing of both rituximab-
sensitive (RSCL) and rituximab-resistant B-cell lymphoma
cell lines (RRCL) [116].
In CLL cells, Hsp90 broadly functions can be reversedwith
17-allylamino-17-demethoxygeldanamycin (17-DMAG)
where it show synergistic cytotoxicity with rituximab [117].
SNX-2112, an oral Hsp-90 Inhibitor, was found to exert aug-
mented antitumor activity when added to rituximab and
bortezomib in rituximab-resistant NHL cells lines, which
make this way into the clinic trial [118].
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Triggering TRAIL/TRAILR along with rituximab
Within the TNF superfamily, tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) has gained prominence
as possible therapeutic modulators owing to its tumoricidal
activity in animal models and in a variety of tumor types, with
no or minimal toxicity towards normal cells [119]. Based on
this promising activity profile, the administration of
mapatumumab, a fully human agonistic mAb directed to
TRAIL receptor 1 (TRAIL-R1) and rituximab has shown en-
hanced antilymphoma efficacy in preclinical models [120].
Dulanermin, a soluble recombinant human apoptosis ligand
2 (Apo2L) or TRAIL, was found to be safe and well tolerated
when combined with rituximab in NHL patients [121].
However, an open-label phase 1b/2 randomized study re-
vealed no added benefit of this combined treatment in relapsed
patients with iNHL [122].
Cell cycle regulators as targets for therapy and combinations
Dysregulation of cell cycle process is one of the hallmarks of
cancer, making it an attractive targets for pharmacological
inhibition. Given the potential benefits of cyclin dependent
kinase (CDK) inhibitors, a study of cyclophosphamide plus
alvocidib, a CDK inhibitor, and rituximab (CAR) is enrolled
for treatment of nine high-risk CLL patients. Combined ther-
apy with CAR was well tolerated, resulted in three CR and
four PR [123]. In a phase I trial, the combination of dinaciclib,
a novel selective inhibitor of cyclin-dependent kinase (CDK1,
2, 5, and 9) with rituximab in relapsed/refractory CLL sub-
jects, was well tolerated and only one patient achieved a CR
[124]. Another Phase I study involved dinaciclib plus rituxi-
mab for CLL and SLL patient [NCT01650727]. A high Skp2,
a p27 (kip1) ubiquitin ligase, expression was found to be
correlated with poor OS and PFS in DLBCL patients who
received R-CHOP regimen [125].
Overexpression of Aurora A can override the spindle as-
sembly checkpoint activity during the mammalian cell cycle
and lead to resistance to microtubule-targeted drugs (MTA,
e.g., taxanes, vinca alkaloids) treatment. Indeed, several stud-
ies have been designed to assess efficacy of Aurora kinase as
single agents or combined with other regimens. Xenograft
experiment using MCL cell lines has shown synergistic ther-
apeutic benefit by combining MLN8237, an Aurora A inhib-
itor, with rituximab and MTA (e.g., docetaxel or vincristine)
[126]. In B cell malignancies, several clinical trials are cur-
rently testingMLN8237 in combination with rituximab and/or
other therapeutic agents (e.g., bortezomib or vincristine)
[NCT01812005, NCT01397825, NCT00651664].
Treatment of DLBCL cell lines with mammalian target of
rapamycin inhibitor everolimus plus rituximab induces G0/G1
cell cycle arrest and decrease the overexpression of p-AKT,
demonstrating a rationale for potential synergistic effect [127].
Of greit interest, combined administration of ON 013105, a
novel benzylstyryl sulfone kinase inhibitor, and rituximab was
found to inhibit MCL proliferation by modulating myeloid
cell leukemia 1 (Mcl-1) expression, an essential protein for
cell growth and survival [128].
For MCL cohorts (based on CD20 and cyclin D1-positive
cells) the addition of BTK inhibitor ibrutinib to rituximab is
active and well tolerated [129]. Combination therapy with
idelalisib as a first-in-class, delta isoform specific, PI3-
kinase inhibitor plus rituximab had durable disease control
in treatment-naïve older patients with CLL. The documented
ORR was 100 % in patients with deletion (17p)/TP53 muta-
tions and 97 % in those with unmutated IGHV and a median
PFS of 36 months [130]. Duvelisib, a novel PI3K-δ,γ inhib-
itor, has also been incorporated into rituximab or
obinutuzumab in subjects with previously untreated CD20+
FL [NCT02391545].
Immunomodulatory drugs-rituximab combinations
Using DLBCL cell lines, lenalidomide treatment was found to
significantly inhibit proliferation of activated B cell–like
(ABC)-DLBCL in vitro, by blocking interferon regulatory
factor 4 (IRF4) expression and the BCR-NF-κB signaling
pathway in a cullin 4-containing ubiquitin ligase complex
(CRL4)-dependent manner [131].
Fecteau et al., showed that lenalidomide can directly inhibit
proliferation of CLL cells in a cereblon- and p21-dependent,
but p53-independent manner [132].
These studies provided the basis for the use of lenalidomide
combinedwith rituximab in NHL, demonstrating its antitumor
effects via the recruitment of NK cells, increased ADCC, im-
proved NK cell–mediated synapse formation, and CD20 cap-
ping [133–137]. Fowler et al., presented data using
lenalidomide combined with rituximab for untreated indolent
lymphoma. Treatment was well tolerated, with an ORR of
98 %, and PFS of 89 %. [138]. Immunologic effects of
lenalidomide through reduction of Tregs number and function
may potentiate the rituximab-mediated ADCC action in pa-
tients with FL who are FcγRIIIa-158 phenylalanine carriers,
resulted in ORR of 46 % with a 2-year PFS of 44 % [139].
In a phase II study lenalidomide-rituximab combination
showed an ORR of 84 % with 53 % CR in patients with
MCL [140]. The feasibility of combining lenalidomide con-
currently with rituximab and bortezomib has been demonstrat-
ed in phase I/II trials of MCL patients. The three-drug therapy
resulted in a 82%ORRwith 32% of patients having a CR and
75 % ORR for patients who did not received prior treatment
The authors suggest that, given the incidence of neuropathy,
subcutaneous or less frequent intravenous (IV) dosing of
bortezomib should be considered rather than the twice-
weekly IV bortezomib used in this study [141].
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A novel immunomodulatory drugs (IMiDs) CC-122, the
pleiotropic pathway modifier, specifically targets CRL4, and
promotes degradation of Aiolos and Ikaros, resulting in a
mimicry of IFN signaling and apoptosis in DLBCL [142].
Consequently, ongoing study is assessing CC-122 combined
with rituximab and two other IMiDs, CC-223, CC-292, in
subjects with DLBCL [NCT02031419].
Histone deacetylase inhibitor-containing drugs
Epigenetic code modifications including altered DNA
methylation and histone acetylation have been proposed
as promising therapeutic targets in B cell malignancies.
Interestingly, recent work has shown that histone
deacetylase inhibition (HDACi) is associated with in-
creased CD20 expression level in DLBCL patients in
vivo, suggesting that pre-treatment with valproate or oth-
er HDACis before anti-CD20 therapy could be beneficial
in CD20-low B-cell lymphomas [59, 143]. In Phase I/II
trial setting, the combination of vorinostat (SAHA) his-
tone de-acetylases (HDACi), cladribine, and rituximab
(SCR) for newly diagnosed MCL produced considerable
response rate and clinical benefit, perhaps correlating
with ADCC activity, CD20 mRNA expression level,
and cyclin D1-A polymorphism [144, 145]. Another trial
of SCR established in patients with relapsed B-cell ma-
lignancies. This compound revealed a trend towards de-
creased expression of multiple tumor suppressor genes
including DUSP1, DUSP 2, and p53 as well as changes
in CD20 mRNA levels, and was well tolerated especially
in patients with previously untreated MCL [146]. The
vorinostat-rituximab combination was found to be con-
siderably safe and active in iNHL with ORR of 46 %.
Although the downregulation of cytokines after treatment
with vorinostat and rituximab demonstrated no increase
in formal response, it is possible that analysis of various
cytokines secretion at different time points would en-
hance the correlation with response outcomes [147].
Another HDACi, panobinostat, is being evaluated in
combination with rituximab for relapsed/refractory
DLBCL [NCT01238692].
Other new combined reagents
A broad range of other novel drugs with various mech-
anisms of action are still under development or in early
stage of clinical studies. Emerging in vitro and in vivo
experimental settings suggested the involvement of
fenretinide (4HPR), synthetic analog of retinoic acid
(RA), and rituximab not only in apoptosis induction of
malignant human B cells but also in elimination of
established tumors and prolongation of survival times in
mice bearing B lymphoma xenografts , favoring
combination arm [148]. Tablostat mesylate exerts inhibi-
tory effects on dipeptidyl peptidase such as fibroblast
activation protein (FAP) and dipeptidyl peptidase IV
(DPP - IV ) a nd s t imu l a t e s a n t i n e op l a s t i c a n d
haematopoesis activities. In xenograft models of human
CD20 + B-cell lymphoma talabostat enhanced the cyto-
toxic efficacy of rituximab [149]. Accordingly, phase II
trial of tablostat plus rituximab in CLL patient who re-
lapse after, or do not respond to fludarabine regimen has
completed; although no results have been reported
[NCT00086203].
Lysophosphatidic acid acyltransferase β (LPAAT-β) iso-
form is a transmembrane enzyme that catalyses the biosynthe-
sis of phosphatidic acid and stimulates a specific G protein–
coupled receptor present in numerous cell types, thereby trig-
gering a multitude of biologic responses. Enzymatic inhibition
of LPAAT-β in combination with rituximab has been linked to
antitumor activity in NHL cell lines and induction of complete
response in human lymphoma xenografts [150]. Importantly,
a recent study have provided interesting clues illustrating
farnesyltransferase inhibitor (FTIs) L-744,832, which report-
edly inhibits prosurvival signaling, has capacity to increase
anti-tumor activity of rituximab and CD20 expression in the
majority of primary NHL or CLL cells [151].
Conclusions
Although clinical outcome for leukemia and lymphoma with
CD20 mAbs has a considerable improvement over the last
decade, the development of resistance in certain patients is
still a major problem. Therefore, new generations of anti-
CD20 mAbs, antibody engineering approaches and antibody
combination therapies with superior inhibitory activity pro-
vide extensive opportunities for treatment of B cell neoplasia.
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